Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: A matched case-control study

Diabetes Research and Clinical Practice

Volumn 82, Issue 3, 2008, Pages 391-395

  Sadikot, Shaukat M ^a   Mogensen, Carl E ^b  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Coronary artery disease (CAD) risk; Sulphonylureas; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; METFORMIN;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DEMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SIDE EFFECT;

ADULT; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RISK; SULFONYLUREA COMPOUNDS;

EID: 55549084500     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.004     Document Type: Article

References (15)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339 (1998) 229-234
2. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet. Med. 23 (2006) 579-593
3. Cefalu W.T. Glycemic control and cardiovascular disease-should we reassess clinical goals?. N. Engl. J. Med. 353 (2005) 2707-2708
4. Bell D.S.M. Do sulfonylurea drugs increase the risk of cardiac events?. CMAJ 174 (2006) 185-186
5. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (Suppl.) (1970) 789-830
6. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin, compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352 (1998) 837-853
7. Gustafsson I., Hildebrandt P., Seibæk M., Melchior T., Torp Pedersen C., Kober L., et al. Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. Eur. Heart J. 21 (2000) 1937-1943
8. Garratt K.N., Brady P.A., Hassinger N.L., Grill D.E., Terzic A., and Holmes D.R. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J. Am. Coll. Cardiol. 33 1 (1999) 119-124
9. Fisman E.Z., Tenenbaum A., Benderly M., Goldbourt U., Behar S., and Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 91 3 (1999) 195-202
10. Davis T.M., Parsons R.W., Broadhurst R.J., Hobbs M.S., and Jamrozik K. Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment. Diabetes Care 21 4 (1998) 637-640
11. Meier J.J., Deifuss S., Klamann A., Schmiegel W., and Nauck M.A. Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp. Clin. Endocrinol. Diabetes 111 6 (2003) 344-350
12. Nathan D.M. Initial management of glycemia in type 2 diabetes mellitus. N. Engl. J. Med. 347 (2004) 1342-1349
13. Meier J.J., Gallwitz B., Schmidt W.E., Mügge A., and Nauck M.A. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 90 (2004) 9-12
14. Stevens R.J., et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. 101 (2001) 671-679
15. Johnsen S.P., Monster T.B.M., Olsen M.L., Thisted H., Mclaughlin J.K., Sørensen H.T., et al. The risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am. J. Ther. 13 (2006) 134-140